Navigation Links
Newer Drug May Help Prevent Fracture in Men With Prostate Cancer
Date:2/24/2011

WEDNESDAY, Feb. 23 (HealthDay News) -- A new drug called denosumab (Xgeva) performed somewhat better than the current standard treatment of zoledronic acid (Zometa) for preventing fractures and other bone problems in men with hormone-resistant prostate cancer, a new study suggests.

In many patients, prostate cancer becomes resistant to initial hormone treatment within the first few years of diagnosis. As a result, tumors begin to grow again and spread to other parts of the body, including bones. This increases the risk of fractures and other bone problems that cause pain and disability, which can greatly reduce a man's quality of life, according to background information in the study.

Helping to prevent these bone troubles can prove very important to these patients, one expert said.

"The successful treatment of osteoporosis, bone pain, and complications of advanced boney disease in men with [castration]-resistant prostate cancer will increase their quality of life considerably," noted Dr. Elizabeth Kavaler, a urology specialist at Lenox Hill Hospital in New York City. She was not involved in the new study.

The research, which was funded by Xgeva's maker, Amgen, was led by Dr. Karim Fizazi of the University of Paris Sud, in France, and included more than 1,900 men. The men were treated for hormone-resistant prostate cancer at 342 centers in 39 countries. They were randomly assigned to receive either 120 milligrams of denosumab, delivered subcutaneously (needle just under the skin) plus an intravenous placebo (950 patients) or 4 milligrams of IV zoledronic acid plus IV placebo (951 patients), given every four weeks.

All the patients were advised to take supplemental calcium and vitamin D to help strengthen their bones. This advice was followed by 90 percent of patients in the denosumab group and 87 percent of those in the zoledronic acid group.

The median time to the first bone problems was just under 21 months in the denosumab group and a little more than 17 months in the zoledronic acid group.

Overall, bone problems occurred in 36 percent of patients who took denosumab and 41 percent of those who took zoledronic acid.

"The 5 percent reduction in skeletal related events, including pathologic fractures and spinal cord compression, seen in the denosumab group versus the zoledronic acid group is very encouraging," Kavaler said. "This is a difficult patient population in that their symptoms related to bone metastases can be debilitating."

Serious adverse events were recorded in 63 percent of patients in the denosumab group and 60 percent of those in the zoledronic acid group.

Of the adverse events most likely related to the treatments, hypocalcaemia (very low calcium concentrations) occurred in 13 percent of patients taking denosumab and in 6 percent of those taking zoledronic acid, while osteonecrosis of the jaw (a debilitating destruction of bone tissue) occurred in 2 percent of the denosumab group and 1 percent of the zoledronic acid group.

The study appears online Feb. 24 in the journal The Lancet.

More information

The U.S. National Cancer Institute has more about prostate cancer.

-- Robert Preidt

SOURCES: Elizabeth Kavaler, MD, urology specialist, Lenox Hill Hospital, New York City; The Lancet Oncology, news release, Feb. 24, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer, more intense chemotherapy with less radiation not more effective against Hodgkins lymphoma
2. Decrease in suicide not linked to newer antidepressants
3. Newer Drugs Beat Gleevec in Head-to-Head Trials
4. In infant heart surgery, newer technique yields better survival in first year of life
5. Newer Genetic Info Adds Little to Predicting Breast Cancer
6. Newer Blood Thinner Beats Plavix for Bypass Patients
7. Newer Genetic Test for Autism More Effective
8. Newer Blood Test Predicts Diabetes, Heart Disease
9. Newer cornea transplant surgery shows short- and long-term promise
10. Antioxidants in pecans may contribute to heart health and disease prevention
11. Bristol-Myers Squibb Foundation awards nearly $1M to HBV, HCV awareness, prevention and care
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Drug May Help Prevent Fracture in Men With Prostate Cancer
(Date:6/26/2016)... ... , ... PawPaws brand pet supplements owned by Whole Health Supply ... health of felines. The formula is all-natural and is made from Chinese herbs that ... Cat Kidney Support Supplement Soft Chews are Astragalus Root Extract and Rehmannia Root ...
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern ... Laude and his M.D from the David Geffen School of Medicine at UCLA. He ... Los Angeles to complete his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... 2016   Bay Area Lyme Foundation , ... Center for Tick Borne Illness , Harvard Medical ... Hacking Medicine, University of California, Berkeley, and the ... five finalists of Lyme Innovation , the ... 100 scientists, clinicians, researchers, entrepreneurs, and investors from ...
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... , June 24, 2016  Arkis BioSciences, a ... invasive and more durable cerebrospinal fluid treatments, today ... The Series-A funding is led by Innova Memphis, ... and other private investors.  Arkis, new financing will ... and the market release of its in-licensed Endexo® ...
Breaking Medicine Technology: